ERBB2 and breast carcinoma: In addition, KDM5-inhibitors have been shown to act synergistically with trastuzumab and lapatinib—two commonly used drugs to treat HER2+ positive breast cancer, in HER2+ breast cancer cells [302], and also induce cell-cycle arrest and senescence in a battery of breast and other cell lines [303].